Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes
Diabetes/Metabolism Research and Reviews Oct 26, 2017
Bouchi R, et al. - The authors examined whether the use of dipeptidyl peptidase 4 (DPP4) inhibitors (DPP4i) could attenuate the progressive loss of muscle mass in patients with type 2 diabetes. In patients with type 2 diabetes, the data implied the potential of DPP4i to prevent the progressive loss of muscle mass with aging.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
